A paper by the MultiOmic team members was published in the May issue of the ICT magazine
What insight can recent trials give us into how molecular-level disease drivers can be used to enter into a new era of precision nephrology?
MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions
MultiOmic Health has closed a £5 million seed extension round to build its precision therapeutics discovery platform for metabolic syndrome.
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
MultiOmic Health forges research collaboration with Northern Care Alliance NHS Foundation Trust in diabetic kidney disease
Honoured to be selected as winners of BIA’s Innovation Showcase in the first ever TechBioUK conference
MultiOmic is proud to announce winning first place in the pitch competition at BIA’s TechBio UK Conference 2022
Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis
In this article, we look at how Mesh Bio and MultiOmic Health use AI to transform and improve the lives of metabolic syndrome patients through patient stratification and precision medicine.
Understanding the AI-enabled Drug Discovery Landscape
An Expert View from Henrietta Bull, science and partnership analyst, and Robert Thong, chief executive, MultiOmic Health.
The Pharma Letter Podcast — Episode 15 — Can AI find new drugs for metabolic diseases?
In this week’s episode of The Pharma Letter Podcast, MultiOmic chief executive Robert Thong discusses his firm’s progress and ambitions for the future.
MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease
MultiOmic Health and Mesh Bio announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease.
Leveraging deep omics data to tackle a global health challenge with precision
We are excited to announce our feature in the most recent edition of Nature Portfolio’s Biopharma Dealmakers discussing the advances in AI-driven drug development.